Journal article
Effect of intravenous alteplase on post-stroke depression in the WAKE UP trial
A Königsberg, S Sehner, S Arlt, B Cheng, CZ Simonsen, F Boutitie, J Serena, V Thijs, M Ebinger, M Endres, JB Fiebach, R Lemmens, KW Muir, N Nighoghossian, S Pedraza, C Gerloff, G Thomalla
European Journal of Neurology | WILEY | Published : 2021
DOI: 10.1111/ene.14797
Open access
Abstract
Background and purpose: The aim was to study the effect of intravenous alteplase on the development of post-stroke depression (PSD) in acute stroke patients, and to identify predictors of PSD. Methods: This post hoc analysis included patients with unknown onset stroke randomized to treatment with alteplase or placebo in the WAKE-UP trial (ClinicalTrials.gov number, NCT01525290), in whom a composite end-point of PSD was defined as a Beck Depression Inventory ≥10, medication with an antidepressant, or depression recorded as an adverse event. Multiple logistic regression was used to identify predictors of PSD at 90 days. Structural equation modelling was applied to assess the indirect effect of..
View full abstractGrants
Awarded by Bristol-Myers Squibb
Funding Acknowledgements
WAKE-UP received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no.278276 (WAKE-UP).